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It is unknown whether patterns of human immunodeficiency virus (HIV)-specific T-cell responses during
acute infection may influence the viral set point and the course of disease. We wished to establish whether the
magnitude and breadth of HIV type 1 (HIV-1)-specific T-cell responses at 3 months postinfection were
correlated with the viral-load set point at 12 months and hypothesized that the magnitude and breadth of
HIV-specific T-cell responses during primary infection would predict the set point. Gamma interferon (IFN-)
enzyme-linked immunospot (ELISPOT) assay responses across the complete proteome were measured in 47
subtype C HIV-1-infected participants at a median of 12 weeks postinfection. When corrected for amino acid
length and individuals responding to each region, the order of recognition was as follows: Nef > Gag > Pol >
Rev > Vpr > Env > Vpu > Vif > Tat. Nef responses were significantly (P < 0.05) dominant, targeted six
epitopic regions, and were unrelated to the course of viremia. There was no significant difference in the
magnitude and breadth of responses for each protein region with disease progression, although there was a
trend of increased breadth (mean, four to seven pools) in rapid progressors. Correlation of the magnitude and
breadth of IFN- responses with the viral set point at 12 months revealed almost zero association for each
protein region. Taken together, these data demonstrate that the magnitude and breadth of IFN- ELISPOT
assay responses at 3 months postinfection are unrelated to the course of disease in the first year of infection
and are not associated with, and have low predictive power for, the viral set point at 12 months.
The identity of T-cell immune responses during early infec-
tion that would serve as a predictor of the viral set point, and
hence disease progression, would be important not only for
understanding pathogenesis, but also for providing insight into
immunological markers that could be used in vaccine trials.
Many studies have utilized the gamma interferon (IFN-) en-
zyme-linked immunospot (ELISPOT) assay for identifying T-
cell immunity during chronic infection and for identifying T-
cell epitopes (1, 13, 16, 28, 29), and it is in current use for
measuring vaccine-induced immunogenicity. Whether IFN-
ELISPOT assay responses, measured during acute infection,
have utility for understanding the course of early disease in
human immunodeficiency virus type 1 (HIV-1) infection re-
mains open to question.
Acute infection is characterized by an explosion of viral
replication, with antigen-specific memory CD4 T cells being
preferentially infected (7, 12), most likely resulting in CD4
depletion mainly in gut-associated lymphoid tissue (8, 30, 39).
Studies of simian immunodeficiency virus (SIV)-infected mon-
keys have shown that a massive loss of CD4 T cells in gut-
associated lymphoid tissue occurs within days of infection (25,
40), and it is thought that immunity to HIV during the acute
stage of infection determines the subsequent course of the
disease. It is known that some individuals can successfully
contain viral replication over years of infection (11), and the
initial rise in HIV-specific CD8 T cells, imparting cytotoxic
T-cell activity, is thought to be one important component in the
control of viremia (6). It is also apparent that virus fitness
interlinked with the host genetic background can contribute to
virus control and the delay of HIV disease progression (2, 9,
17, 20).
The identity of important host immune responses has shown
that CD8 T-cell recognition of Gag is associated with control
of HIV replication (22, 28, 33, 43) and that a broad spread of
epitopes recognized within Gag appear to be correlated with
low viremia (22), which may impact viral fitness. Some studies,
including our own, found correlations between preferential
recognition of Gag and the viral load (13, 28), with other
studies finding no associations (1). It is possible that these
association differences are due to the types of cohorts investi-
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gated and the time since infection, with most studies being
performed at the chronic stage of infection.
While there have been many studies investigating the rela-
tionship between cytotoxic-T-lymphocyte (CTL) responses in
chronic infection and disease progression, there have been few
studies to show whether these associations hold true during the
acute and primary stages of infection. Events in acute infection
may be critical for governing the subsequent course of disease
but are also pertinent for identifying clues to vaccine-induced
immunity. This study investigates the relationship between the
magnitude and breadth of T-cell responses in primary infection
and the viral load at 12 months postinfection, with the latter
measurement being used as a surrogate marker for disease
progression. We hypothesized that the magnitude and breadth
of HIV-specific T-cell responses during primary infection
would be correlated with the viral set point.
MATERIALS AND METHODS
Study subjects. An ongoing longitudinal cohort of acutely HIV-1-infected
individuals were enrolled as part of the Centre for AIDS Programme Research
in South Africa (CAPRISA) 002 acute-infection study in Durban, South Africa
(38). We report on 47 individuals in the cohort. The time postinfection was
estimated by a prospective RNA-positive/antibody-negative measurement or was
taken as the midpoint between the last antibody-negative test and the first
antibody-positive enzyme-linked immunosorbent assay. The study cohort wasn
described previously (38), when study participants were followed for up to 24
months, and the study is still ongoing; data from events within the first 3 to 12
months are reported here. The University of KwaZulu-Natal, University of
Witwatersrand, and University of Cape Town Ethics Committees approved this
study, and all the subjects provided written informed consent for participation in
the study.
Plasma viral-load determination, CD4 T-cell counts, and HLA typing. Plasma
HIV-1 RNA levels were quantified using the Cobas Amplicor HIV-1 monitor
test version 1.5 (Roche Diagnostics, Branchburg, NJ). Absolute blood CD4
T-cell counts were determined using the FACSCalibur flow cytometer and were
expressed as cells/mm3. High-resolution HLA typing was performed as previ-
ously described (29).
Synthetic subtype C peptides. A set of 432 synthetic overlapping peptides
spanning the entire expressed HIV-1 clade C proteome corresponding to gene
products from the HIV-1 consensus C (Gag, Vif, Vpr, and Vpu), isolate Du151
(Pol, Nef, Tat, and Rev), and isolate Du179 (gp160 Env) were synthesized using
9-fluorenylmethoxy carbonyl chemistry and standard-based solid-phase tech-
niques (Natural and Medical Sciences Institute, University of Tubingen, Tubin-
gen, Germany). The nonconsensus synthesized peptides were based on se-
quences from isolates used for the manufacture of a clade C vaccine (42). The
estimated purities of the peptides were 80% as measured by high-performance
liquid chromatography and mass spectrometry. Individual peptides were diluted
in dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO) and prepared as previously
described (28).
Cell preparation, generation of cell lines, and HLA restriction. Peripheral
blood mononuclear cells (PBMC) were isolated by standard Ficoll-Hypaque
density gradient centrifugation (Amershan Pharmacia, Uppsala, Sweden), cryo-
preserved in 90% heat-activated fetal bovine serum (Invitrogen, Paisley, United
Kingdom) plus 10% dimethyl sulfoxide, and stored in liquid nitrogen until they
were needed. The frozen PBMC were thawed and rested in RPMI 1640 (Invitro-
gen, Paisley, United Kingdom) containing 10% heat-inactivated fetal bovine
serum and 50 U gentamicin 50 (Invitrogen, Paisley, United Kingdom) at 37°C
and 5% CO2 for 18 h prior to use in ELISPOT assays. Epstein-Barr virus-
transformed B-cell lines for use as class I HLA-matched targets were established
for each individual and maintained in RPMI 1640 supplemented with 20% fetal
calf serum and 50 U of gentamicin (R20) at 37°C, 5% CO2. PBMC (106) were
stimulated with 10 g peptide and 330 U/ml interleukin 7 (IL-7) (Roche), and
the cells were transferred to a 24-well plate and incubated at 37°C, 5% CO2.
After 1 week in culture, 25 U/ml of IL-2 was added, and after 14 to 21 days in
culture, PBMC (effectors) were harvested for use in a standard 51Cr release
assay. HLA-matched B cells (targets) were pulsed with 10 g peptide and 100 to
150 Ci of 51Cr for 1 h at 37°C, 5% CO2. Following extensive washing with 1%
fetal calf serum (FCS) in RPMI, the B cells were resuspended in 10% FCS in
RPMI and mixed with effectors in triplicate at a 50:1 and 25:1 effector/target
ratio in V-bottom 96-well plates, and the killing assay mixture was incubated for
4 to 5 h at 37°C, 5% CO2. Twenty-five microliters of the supernatant was
harvested onto LumaPlates-96 (Packard Bioscience, Billerica, MA) and allowed
to dry overnight, and the radioactivity was detected using a gamma counter
(TopCount-NXT; Packard Bioscience). Spontaneous release of 51Cr was deter-
mined by incubating targets with R10, and the maximum release was determined
from the total radioactivity released by the targets in the presence of 0.01% Triton
X-100. Specific lysis (percent) was calculated as follows: (experimentalaverage 
spontaneousaverage)/(maximumaverage  spontaneousaverage)  100.
IFN- ELISPOT assay. HIV-1-specific T-cell responses were quantified by the
IFN- ELISPOT assay using the set of overlapping peptides arranged in a
pool-matrix format as previously described. Briefly, PBMC were plated at 1 
105 cells/ml with peptides at a concentration of 2 g/ml in 96-well polyvinylidene
difluoride plates (MAIP S45; Millipore, Johannesburg, South Africa) that had
been coated with 5 g/ml anti-IFN- monoclonal antibody 1-DIK (Mabtech,
Stockholm, Sweden) overnight at 4°C. Phytohemagglutinin (Calbiochem, San
Diego, CA) stimulation at 4 g/ml was used as a positive control, and no peptide
stimulation (medium alone) was used as a negative control. As part of an
ongoing quality assurance program, thawed PBMC that had been tested previ-
ously for responses to a pool of optimal peptides corresponding to cytomegalo-
virus, Epstein-Barr virus, and influenza viruses were included on the same plate
as a positive quality control sample for assay consistency. The plates were incu-
bated overnight at 37°C, 5% CO2, and developed as previously described. Indi-
vidual spots were counted with an automated ImmunoSpot plate reader (Cellu-
lar Technology Ltd., Cleveland, OH) and expressed as spot-forming units (SFU)
per million PBMC. Responses were initially evaluated by reacting PBMC with
peptides arranged in a pool-matrix format and followed with a second ELISPOT
assay on selected participants to confirm positive responses at the single-peptide
level in triplicate. The following criteria were used to define positive responses:
(i) reactivities to peptide pools of 67 SFU/106 PBMC after background sub-
traction and at least three times greater than the mean background activity and
(ii) a matching peptide in the matrix pool array. Peptide truncations correspond-
ing to immunodominant peptides in Nef were generated and used in an
ELISPOT assay to identify the optimal epitope. A total of 100,000 PBMC per
well were incubated with the truncated peptides at different concentrations from
0.2 to 2,000 ng/ml in an ELISPOT assay as described previously. The optimal
epitope was defined as the peptide that induced the highest specific IFN-
production at the lowest peptide concentration.
TABLE 1. Clinical details of the cohort at enrollment and 12 and 48 to 56 weeks postinfection
Parameter
Value at:












Mean 6.1 4.73a 546 12.3 4.46 559b 52 4.33a 471b
95% confidence
interval limits
4.45–5.0 482–609 4.21–4.71 490–628 4.04–4.62 405–537
Range 2.73–6.17 197–989 2.6–5.79 255–1,358 2.6–6.22 174–1,093
a P  0.01.
b P  0.05.
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Statistical analysis. Statistical analysis and graphical presentation were per-
formed using InStat and GraphPad Prism version 3.0 software. Data are ex-
pressed as median values with interquartile ranges and were analyzed by the use
of nonparametric statistics. Statistical analysis of significance was performed with
either Mann-Whitney or Kruskal-Wallis analysis of variance using Dunn’s test
for multiple comparisons. All tests were two tailed, and a P value of 0.05 was
considered statistically significant. The relationships between the plasma viral
load, CD4 T-cell counts, CD4 slopes, and the breadth or magnitude of HIV-
specific T-cell responses were analyzed using Spearman rank correlations. Cor-
relations with the viral load were made by transforming RNA copies/ml to log10
copies.
RESULTS
Study subjects. Forty-seven subtype C HIV-1-infected par-
ticipants in the CAPRISA 002 acute-infection study were re-
cruited within a mean of 6.1 weeks after infection (Table 1),
and responses across the complete proteome were measured
using the IFN- ELISPOT assay at a median of 12 weeks and
a range of 10 to 17 weeks postinfection. Table 1 shows the
mean log10 RNA copies and CD4 counts at three time points
during the first year of infection (at enrollment and 12 and 48
to 56 weeks postinfection), showing an overall decline in vire-
mia of 0.4 log10 copies across the cohort, with a significant
parallel reduction of 75 CD4 cells/ml.
HIV-specific IFN- T-cell responses at 3 months postin-
fection are dominated by recognition of Nef. Nef responses
were found to be highly dominant at 12 weeks after infection.
Figure 1A shows the cumulative magnitude of IFN- ELISPOT
FIG. 1. Magnitude, frequency, and hierarchy of IFN- ELISPOT assay responses at 3 months postinfection. (A) Cumulative magnitude of
IFN- ELISPOT assay responses across the expressed subtype C HIV-1 genome showing statistical significance between Gag, Pol, Vif, Vpu, Env,
and Nef. The magnitude is shown as the total response of all pools for each region, and each point represents a response per participant measured
as SFU/million PBMC. Vertical lines represent the interquartile ranges. (B) Order of the corrected magnitudes of IFN- ELISPOT assay responses
across the genome, calculated by dividing the total magnitude (SFU/106 PBMC) of the response per protein by the amino acid length for each
protein and expressing it as a proportion of responders for that region. (C) Pie chart showing the amino acid stretches (corresponding to peptide
pools) recognized within Nef. (D) Identification of two optimal epitopes in Nef using truncated peptides and HLA restriction killing assays. The boxed
sequences in the truncation experiments were the optimal epitopes giving the highest IFN- ELISPOT readout at the lowest peptide concentration. The
optimal epitope was then used in HLA restriction experiments, where the partial mismatched B-lymphoblastoid target that gave the percent specific CTL
lysis at 25:1 and 50:1 effector/target ratios closest to that of the autologous B-cell line provided the restricting allele. The boxed HLA types are the HLA
alleles giving the highest CTL response that matched the autologous HLA background. The data were generated from an early infection cohort reported
previously (4).
472 GRAY ET AL. J. VIROL.
assay responses per expressed gene region, where the hierarchy
of the total sum of responses was as follows: Nef (56,380
SFU/106 PMBC)  Pol (29,610 SFU/106 PMBC)  Gag
(18,868 SFU/106 PMBC)  Env (16,995 SFU/106 PMBC) 
Rev (12,550 SFU/106 PMBC)  Vpr (5,098 SFU/106 PMBC)
 Vpu (2,038 SFU/106 PMBC)  Vif (508 SFU/106 PMBC) 
Tat (430 SFU/106 PMBC). When corrected for responses per
amino acid to account for the density of responses per ex-
pressed gene, and on a per responder basis, the order of rec-
ognized proteins became Nef  Gag  Pol  Rev  Vpr 
Env  Vpu  Vif  Tat (Fig. 1B), with Nef being highly
immunodominant. Figure 1C shows which regions of Nef were
targeted, where there was a uniform distribution of responses
between amino acids 1 and 171, and there was little recognition
in the more hypervariable N terminus of Nef (amino acids 172
to 206).
Narrow and focused recognition of Nef. The majority of
responses within Nef involved six recognized peptides, with
multiple possible epitopes within each stretch. Table 2 shows
the six peptides frequently recognized, where over 70% of
responses were accounted for by three peptides in pool 3
(77RPMTYKAAFDLSFFLKEKG95, 101IHSKRRQDILDLW
VYYHTQG119, and 113WVYHTQGYFPDWQNYTPGP131).
The CTL epitopes that are embedded within each of these
peptides have been described (23), except for the one found
toward the N terminus of Nef (Table 2). The peptide corre-
sponding to the most dominant response (80%; 129PGPGVR
YPLTFGWCFKLVP147) possessed up to six previously de-
scribed epitopes, and we were able to show in two additional
peptide stretches, 77RPMTYKAAFDLSFFLKEKG95 and 101I
HSKRRQDILDLWVYYHTQG119, two unique HLA-re-
stricted epitopes: B*5703, restricting AAFDLSFFL, and B*1302,
restricting RQDILDLWIV (Fig. 1D and Table 2). Together,
these data show that narrowly focused responses to selected
epitopes in Nef during acute HIV-1 subtype C infection account
for the majority of IFN- ELISPOT assay responses.
HIV-specific IFN- T-cell responses at 3 months postin-
fection are not associated with the course of viremia in the first
12 months. To assess whether quantitative differences in HIV-
1-specific cellular immune responses in the first few weeks of
subtype C HIV-1 infection were related to the direction of
viremia over the first 12 months of infection, we tested for an
association between IFN- ELISPOT assay responses and
changes in the viral load between 3 and 12 months. We based
our analysis on the hypothesis that the magnitude of early
HIV-specific T-cell responses at 3 months would determine the
course of viremia. Teasing out individual viral-load changes
within the cohort revealed positive and negative differences in
viremia between 3 and 12 months. Figure 2A show the changes
in log10 viremia, where some individuals showed a 1-log10
unit increase in viremia and some displayed 1-log10 unit-
lower viremia. We used these differences to track the course of
viremia for each participant and to relate these changes with
the IFN- ELISPOT assay response profile for each partici-
pant. Figure 2B shows the total proportions of ELISPOT assay
responses across the expressed genome for each participant as
a heat map, where no discernible response profile was evident
in relation to viral-load differences (Fig. 2A). Figure 2C quan-
tifies this lack of association with the direction of viremia over
the first year. As shown in Fig. 1A to C and Table 2, focused
responses to Nef were omnipresent regardless of the negative
or positive changes in the viral load at 12 months. We also
examined whether responses at 6 months were associated with
changes in the viral load over 12 months and identified a
similar lack of association (data not shown). Also notable was
the lack of association between the viral load and responses to
Gag (Fig. 1C), which differs from our previous findings (28) in
a cohort examined around 12 months after infection.
HIV-specific IFN- T-cell responses at 3 months postin-
fection are not associated with early disease profiles. By addi-
tionally factoring in the course of absolute CD4 cell count
changes, we were able to define disease profiles in the first year
of infection according to rapid, intermediate, and slow pro-
gression. Rapid progressors were defined as those who had
CD4 cell counts consistently below 350 cells/ml between 10 and
15 months postinfection. Slow progressors were defined as
having viral loads consistently below 2,000 RNA copies/ml
between 10 and 15 months postinfection, and intermediate
TABLE 2. Reactive peptides in Nef pools 2 to 5, magnitudes of response, frequencies, and known epitopes within the sequence
Reactive-peptide sequence % Responders(no./total)





EVGFPVRPQVPLRPMTYKA 16 (3/9) 554  214 390–960 FPVRPQVPL (B7; B3501); RPQQVPLRPM
(B4201; B8101); PQVPLRPMTY (B35);
QVPLRPMYTK (A3; A11); VPLRPMTY
(B35; B42); PLRPMTYK (A11)
RPMTYKAAFDLSFFLKEKG 36 (9/25) 382  320 110–1,255 KAAFDLSFF (B5701; B5801); AAFDL
SFFL (B5703); DLSFLKEK (A3; A11)
IHSKRRQDILDLWVYYHTQG 24 (6/25) 1,240  1,113 150–3,915 RQDILDLWV (B1302); RQDILDLWVY
(Cw07; B7); ILDLWVYHT (A2)
WVYHTQGYFPDWQNYTPGP 12 (3/25) 1,567  1,578 145–3,710 YHTQGYFPDW (B17); HTQGYFPDW
(B57; B5801); TQGYFPDWQNY (B15);
GYFPDWQNY (A24); YFPDWQNY
(A29; B57; B5801); YFPDWQNYT (A01)
PGPGVRYPLTFGWCFKLVP 80 (8/10) 2,005  1,503 170–4,800 TPGPGVRYPL (B7;) GPGVRYPLTF
(B35); VRYPLTFGW (B27); RYPL
TFGW (A2301; A24); YPLTFGWCF
(B18; B35; B5301); LTFGWCFKL (A2)
NNCLLHPMSQHGMEDADRE 14 (1/7) 570  169 No previously defined epitopes
a From reference 23.
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progressors were defined as those who fit in neither the rapid
nor the slow category. We were able to validate the usefulness
of using CD4 counts in our definition of slow and rapid pro-
gressors by associating CD4 slopes with the viral set point at 12
months (Fig. 3A). Across the complete group, there was a
strong relationship between loss of CD4 cells and a high set
point and between a positive CD4 slope and a low set point.
Additionally, when we compared the subset of individuals who
we classified as slow or rapid progressors (n 	 4 and 8, respec-
tively), we found that in those who were progressing slowly and
controlling viremia, there was a median positive CD4 slope
compared to the median negative slope found in the individ-
uals classified as rapid progressors (Fig. 3A, inset). We then
wished to identify whether the magnitudes of ELISPOT assay
responses across the proteome had any relationship with CD4
slopes and hence with the clinical course of disease in the first
year of infection. No association existed (r ranged from 0.018
to 0.002) between the magnitudes of ELISPOT assay re-
sponses and the CD4 slopes, suggesting that T-cell responses
measured during primary infection had no bearing on the
clinical measurement of disease progression.
The total magnitude and breadth (defined as the number of
peptide pools recognized) of responses for each participant are
shown in Table 3. Although there was no difference in the
mean magnitude of response between slow and rapid progres-
sors, there was a nonsignificant trend of increased breadth of
response (mean, four to seven pools). It is possible that with a
larger sample size, increased breadth might reveal a significant
proportional response with the viral load and might indicate
that an early broad response is not related to subsequent virus
control. Interestingly, there was no response to any protein at
3 months in individual CAPRISA 269 (CAP269), despite virus
control (Table 3). By mapping single peptide responses in the
subset of four controllers and eight rapid progressors, we
showed that rapid progressors possessed a diverse epitope rec-
ognition pattern, with Nef and Vif being dominant (8 and 6
FIG. 2. Association of viral-load differences between 3 and 12 months with the magnitudes of ELISPOT assay responses at 3 months.
(A) Tracking of log10 RNA copies/ml between 3 and 12 months for each of the 47 participants arranged from negative to positive differences
between the two time points. The dotted line demarcates the calculated 95% confidence limits for the mean of three log10 viral-load measurements
between 48 and 56 weeks postinfection (0.58 log10 RNA copies/ml) (Table 1). (B) Heat map reflecting the proportions of Gag; Pol; combined Vif,
Vpr, Tat, Rev, and Vpu (VVTRV); and Env responses out of the total ELISPOT assay response across the complete proteome for each participant
at 3 months. Statistical differences in the proportions of responses are shown (, P  0.05, and , P  0.001). (C) Spearman rank correlations
between the percent responses for Gag, Pol, Env, and Nef and the difference in log10 RNA copies/ml between 3 and 12 months.
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peptides, respectively, out of a total of 30 detected). Out of the
eight rapid progressors, only two peptides in Gag could be
identified (in individuals CAP008 and CAP210). As we had
data for single-peptide responses from only two slow progres-
sors, it was not possible to draw any conclusions or interpret
differences between slow and rapid progression. What was
notable, however, was that many of the peptide responses in
both slow and rapid progressors matched previously described
epitopes when the HLA allele background of each individual
was taken into account (Table 3). Although fine mapping of
epitopes and HLA restrictions was not performed, these data
imply that globally common epitope responses are elicited
during acute subtype C HIV-1 infection.
Lack of correlation between HIV-specific IFN- T-cell re-
sponses and the viral load at 12 months postinfection. We
wished to assess whether HIV-specific IFN- T-cell responses
measured at 3 months postinfection were correlated with the
viral load at 12 months, with the aim of identifying if responses
at 3 months could predict the set point. The set point was
defined as the viral load at 12 months postinfection. To ac-
count for viral spikes, we calculated the mean log10 plasma
RNA copies/ml at three time points around 52 weeks, ranging
from 48 to 56 weeks. Correlating the magnitude and breadth of
IFN- responses with the viral set point at 12 months revealed
low (i.e., close to zero), nonsignificant associations for each
protein region. Figure 3B shows plots of Spearman coefficients
for the total magnitude and breadth of response for each
region, depicting 95% confidence intervals. When the re-
sponses were normalized based on the number of peptides in
the pool (i.e., response per peptide), there was similarly no
significant association with the viral load at 12 months (data
not shown). We also found that there were no associations with
the set point when subregions within Gag, Pol, and Env were
analyzed, namely, p17, p24, RT, integrase, gp41, and gp20
(data not shown). The breadth of response ranged from 0 to 11
peptide pools, with an average of 5.7  3 pools. We initially
hypothesized that early, broad recognition of epitopic regions
would be important for virus control, as broader recognition of
epitopes by HIV-1-specific T cells appears to be associated
with virus control (22, 33). Depicting the 95% confidence in-
tervals provided us with enough evidence to say that neither
magnitude nor breadth, at the full protein level, is associated
with the viral set point at 12 months, and together with the data
shown in Fig. 2, we can conclude that IFN- ELISPOT assay
responses at 3 months have no predictive power for the set
point.
DISCUSSION
The ability to define immune responses early after HIV-1
infection that provide the foundation for controlling disease is
a major focus of AIDS research. The role of CD8 T cells in
the initial control of viremia is well known (6, 24), and there is
evidence to show that in SIV-infected macaques, CD8 cells
play a role in controlling viremia (19, 36), although this may
not necessarily be the case in the natural host of SIV (4). Most
studies of HIV-infected humans have examined antigen-spe-
cific CD8 T-cell responses during chronic disease (1, 10, 15),
and fewer studies have been performed with those controlling
(5) or progressing in (37) the disease. Immunological re-
sponses in acute infection are thought to be crucial for con-
trolling initial viral replication and may predict the subsequent
viral set point.
Our study is the first to identify HIV-specific T-cell re-
sponses during the first few weeks of HIV-1 infection and to
correlate these responses with the subsequent viral load and
FIG. 3. Correlation of CD4 slopes with the viral set point and of the IFN- ELISPOT magnitude and breadth with the viral set point.
(A) Correlation plot of log10 RNA copies/ml at the set point with CD4 slopes. CD4 slopes were calculated in Prism and utilized a mean of 15 
1.6 CD4 measurements over 52 weeks. The dashed line depicts zero slope. CD4 slope differences between slow (n 	 4) and rapid (n 	 8)
progressors are shown in the inset. Box and whisker plots show median and interquartile range limits for CD4 slopes. The sloping line is the best-fit
line. (B) Spearman correlation coefficients with 95% confidence intervals for the magnitudes and breadths of Gag-, Env-, Pol-, and Nef-specific
T-cell responses with the viral set point at 12 months.
VOL. 83, 2009 HIV-SPECIFIC IFN- ELISPOT AND SUBTYPE C SET POINT 475
with disease progression in the first year. We defined primary
infection as that within the first 3 months of infection, and we
screened, in a comprehensive manner, IFN--specific re-
sponses across the proteome using the ELISPOT assay. We
found that responses to Nef were highly immunodominant,
with recognition being focused on a few epitope regions, and
that responses to other regions were less recognized. Overall,
there was no significant relationship between the magnitude of
IFN- ELISPOT assay responses and the course of viremia,
early disease progression, or the set point.
Our study examined a subtype C HIV-1 acute-infection co-
hort recruited in Kwa-Zulu Natal, the province in South Africa
worst hit by the HIV-1 epidemic, which we have followed for
more than 2 years (38). We hypothesized that Gag-specific
T-cell responses established early after infection would be as-
sociated with virus control and a low set point based on prior
data showing that preferential targeting of Gag regions was
associated with low viral loads (28). Similarly, others have
shown the fundamental importance of responses to Gag (13,
33) in virus control, where transmission of an attenuated
B*5801-restricted TW10 epitope in Gag resulted in persis-
tently lower viremia in the new host (9). It would thus appear
that recognition of key epitopes in Gag can attenuate viral
replication and hence disease progression. In the present
study, we found that only 60% of individuals at 3 months
postinfection responded to p17, p24, or both regions in Gag
and identified only minimal epitope responses among slow
progressors who showed virus control within the first year of
infection. It has been shown that some epitope responses in
Gag that dominate chronic infection may not be present during
initial infection (18), and we speculate from our data that
epitopes in Gag have yet to emerge at 3 months postinfection
and that the effect of Gag targeting impacts virus control only
during later, more established infection.
The viral set point has been defined as stable viremia over
time, and from subtype B infections, viremia has been shown to
reach a peak following transmission and then to drop to a
hypothesized set point, which has been shown to be inversely









CAP045 11,400 8 A*2301/2902 B*1510/4501 Cw*0602/1601 Vif p10, Rev p7-8,
Nef p33-34
Vif, WHLGHGVSI (B*1510); Rev,
IHSISERIL (B*1510); Nef, RYP
LTFGW (A*2301)
CAP061 345 3 A*6602/6802 B*1401/4201 Cw*0802/1701 ND
CAP222 2,970 5 A*3001/3303 B*5301/8101 Cw*0401/- Gag p25, Nef p17-18 Gag, TPQDLNTML (A*4201,
B*8101, B*0702); Nef, RPQVP
LRPM (B*4201), QVPLRP
MTYK (A*0301)
CAP269 0 0 A*0205/6802 B*0702/5802 Cw*0602/0611 Nil
Rapid progressors






(A*2301, A*2402); Rev, IHSIS
ERIL (B*1510); Env, LQREWE
VLKYLGSLVQYW; Nef, KRQ
DILDLWIY (Cw*0701)
CAP037 5,130 4 NDd ND ND Pol p51, Nef p2-3,
Nef p33-34
Pol, TVQPIQLPEKDSWTVNDI;
Nef, AVRERMRRT (B7, B8),
RYPLTFGW (A*2301), YPLTF
GWCF (B*5301, B*18, B*35)
CAP065 5,950 11 A*2301/6802 B*1510/5802 Cw*0511/0611 Pol p77-78, Vpr p4,









CAP206 8,040 10 A*3204/7412 B*0702/4403 Cw*0210/0702 Env p54, Nef p32-33 Env, RIKQIINMW (A*3201); Nef,
TPGPGVRYPL (B*0702)




CAP224 1,985 6 ND ND ND Vif p6, Vif p21, Vpr
p4, Nef p17-19





CAP258 12,440 9 A*2301/2902 B*4101/4201 Cw*1701/- Pol p54-55, Vif p6-7,
Vpr p4, Vpu p7,
Env p27, Nef
p33-34




Env, SFDPIPIHY (A*29); Nef,
RYPLTFGW (A*2301)
a Total ELISPOT assay response. Means: early controllers, 3,679  5,315; rapid progressors, 5,765  3,992.
b Breadth at 3 months postinfection. Means: early controllers, 4  3.4; rapid progressors, 7  3.
c Previously identified HLA restricted epitopes corresponding to participant HLA type (23).
d ND, not determined.
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correlated with the time to disease progression (31, 32, 35). It
has been shown that a single measurement 12 to 18 months
post-HIV infection was the most predictive of disease progres-
sion (27), although others have determined set point viral loads
as a composite series of measurements starting earlier, around
6 months after infection (14). In this study, we defined the set
point as a composite of three measurements around 12
months, although we realize that stable viremia may never be
reached (41). We thus determined that neither the magnitude
nor the breadth of responses to any region in the expressed
subtype C genome, utilizing the IFN- ELISPOT assay, during
early infection had any predictive power for the viral set point
at 1 year. This implies that either the IFN- ELISPOT assay is
not able to identify relevant early responses or the character
of the initial immune response that may dictate the course of
viremia is more complex than the magnitude and breadth of
response at one time point. Another caveat to our findings is
the possible viral sequence divergence from autologous
epitopes and the peptide sets used in this study. It is possible
that using peptides based on autologous infecting strains might
have yielded stronger associations than our peptide sets, which
were based on a mixture of consensus Gag and subtype C HIV
vaccine-matched strains (42).
What is also clear from this study is the overwhelming and
ubiquitous targeting of Nef that appears to be focused on six
epitope regions. Nef dominance during primary infection has
also been identified in subtype B infection (26), as well as in
our previous studies of early subtype C infection (28), in which
we showed that responses are positively correlated with the
viral load. Additionally, variant Nef epitopes transmitted from
donor to recipient in transmission studies showed no impact on
viremia (17). Taken together, responses to Nef are unlikely to
play a role in determining virus control or disease progression.
The lack of predictive power of IFN--dependent responses
at 3 months postinfection for subsequent viral loads and set
point is likely due to a multitude of factors. There is no doubt
that IFN- responses during chronic infection identify specific
epitopes that impact virus control (22), but it remains to be
seen whether other cytokine markers may predominate during
acute infection. Our data showed that no association existed
between the IFN- ELISPOT assay magnitude and breadth at
3 months and the viral load at any time, although it is possible
that important responses during early infection may consist of
other cytokines, such as IL-2 or tumor necrosis factor alpha.
We additionally speculate that increasing viral diversity during
the first year of infection would render an early static T-cell
measurement redundant. It has recently been shown that in
more than 75% of acutely subtype B-infected individuals a
single virus is transmitted (21). The ensuing viral diversifica-
tion that occurs after transmission, as the disease becomes
established, is likely shaped by immune pressure and escape (3,
34), resulting in diverse and variant epitope changes over time.
If it is likely that important “critical” responses to Gag emerge
only later during infection (18), could it be that the highly
focused and dominant response to Nef during acute infection
is at the expense of other responses and thus allows viral
propagation? Knowing that attenuating mutations in key
epitopes, rather than the magnitude or breadth of T-cell re-
sponses, may be important contributors to establishing virus
control (9), could it be that the set point has more to do with
the accumulation of CTL mutations?
Our data thus bring into question the utility of using the
IFN- ELISPOT assay for assessing the impact of T-cell im-
munity on the viral set point. It is possible that measuring more
specific immune responses at the single-peptide level may pro-
vide greater insight into epitope changes that may be associ-
ated with a high or low set point. It is also possible that IFN-
alone does not reflect the status of T cells that are associated
with viremia, especially as it has been shown that polyfunc-
tional CD8 T-cell responses may serve as markers of virus
control (5). It is also possible that CD8 memory may play an
important role and that the early status of memory differenti-
ation could provide a more robust predictive marker for virus
control. The current quest for identifying immune correlates of
protection relies on studying acute HIV-1 infection, and the
earliest responses may establish the foundation for subsequent
virus control. We have shown here that defining these re-
sponses using the IFN- ELISPOT assay is unlikely to provide
the necessary immunological insight.
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